Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
What Causes Myelodysplastic Syndromes?
Some cases of myelodysplastic syndrome (MDS) are linked to known risk factors, but most often, the cause is unknown.
Scientists have made great progress in understanding how certain changes in the DNA in bone marrow cells may cause MDS to develop. DNA is the chemical that makes up our genes, which control how our cells function. We usually look like our parents because they are the source of our DNA. But DNA affects more than the way we look.
Some genes control when our cells grow, divide into new cells, and die:
- Certain genes that help cells grow, divide, and stay alive are called oncogenes.
- Genes that help keep cell division under control, or cause cells to die at the right time are called tumor suppressor genes.
Cancers can be caused by gene mutations (defects) that turn on oncogenes or turn off tumor suppressor genes.
Usually mutations in several different genes inside bone marrow cells are needed before a person develops MDS. Some of the mutations most often seen in MDS cells include those in the DNMT3A, TET2, ASXL1, TP53, RUNX1, SRSF2, and SF3B1 genes. Some of these gene changes can be inherited from a parent, but more often they happen during a person’s lifetime.
Inherited gene changes
Researchers have found the gene changes that cause some rare inherited syndromes (like familial platelet disorder with a propensity to myeloid malignancy) linked to an increased risk of developing MDS. This syndrome is caused by inherited changes in the RUNX1 gene. Normally, this gene helps control the development of blood cells. Changes in this gene can lead to blood cells not maturing like they normally would, which can increase the risk of developing MDS.
Gene changes acquired during a person’s lifetime
Often, it’s not known why people without inherited syndromes develop MDS.
Some outside exposures can lead to MDS by damaging the DNA inside bone marrow cells. For example, tobacco smoke contains chemicals that can damage genes. Exposure to radiation or certain chemicals such as benzene or some chemotherapy drugs can also cause mutations that lead to MDS.
But sometimes the gene changes that lead to MDS seem to occur for no apparent reason. Many of these gene changes are probably just random events that sometimes happen inside a cell, without having an outside cause.
Gene changes inside cells can build up over a person’s lifetime, which might help explain why MDS largely affects older people.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391-2405.
Aster JC, Stone RM. Clinical manifestations and diagnosis of the myelodysplastic syndromes. UpToDate. 2017. Accessed at https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes on October 4, 2017.
Komrokji RS, Padron E, List AF. Chapter 111: Myelodysplastic syndromes. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.
Steensma DP, Stone RM. Chapter 99: Myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014.
Last Revised: January 22, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.